On November 5, 2020 InnoCare Pharma (HKEX: 09969), a clinical-stage biopharmaceutical company, reported that the company will present latest clinical data of its BTK inhibitor Orelabrutinib at the 62nd American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting on December 5-8, 2020, which will be held online (Press release, InnoCare Pharma, NOV 5, 2020, View Source [SID1234570180]). The study in Patients with Relapsed or Refractory Mantle Cell Lymphoma, led by Dr. Jun Zhu, and the study in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Cell Leukemia, led by Dr. Jianyong Li, will be presented in three posters. This is the second consecutive year for InnoCare to present Orelabrutinib data at ASH (Free ASH Whitepaper).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Poster Presentation 1：
Title：Pooled Analysis of Safety Data from Clinical Trials of Orelabrutinib Monotherapy in Hematologic Malignancies
Abstract Number：1140
Session Name: 623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies: Poster I
Session Date: Saturday, December 5, 2020
Presentation Time: 7:00 AM-3:30 PM
Location: Poster Hall (Virtual Meeting)
Presenter: Yuqin Song, M.D., Ph.D.
Abstract website: View Source
Poster Presentation 2：
Title：Long-Term Safety and Efficacy of Orelabrutinib Monotherapy in Chinese Patients with Relapsed or Refractory Mantle Cell Lymphoma: A Multicenter, Open-Label, Phase II Study
Abstract Number：2048
Session Name: 623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies: Poster II
Session Date: Sunday, December 6, 2020
Presentation Time: 7:00 AM-3:30 PM
Location: Poster Hall (Virtual Meeting)
Presenter: Yuqin Song, M.D., Ph.D.
Abstract website: View Source
Poster Presentation 3：
Title：Updated Results from the Phase II Study of Orelabrutinib Monotherapy in Chinese Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Cell Leukemia
Abstract Number：1320
Session Name: 642. CLL: Therapy, excluding Transplantation: Poster I
Session Date: Saturday, December 5, 2020
Presentation Time: 7:00 AM-3:30 PM
Location: Poster Hall (Virtual Meeting)
Presenter: Wei Xu, M.D.
Abstract website: View Source
InnoCare will release detailed Orelabrutinib clinical data during ASH (Free ASH Whitepaper) meetings.
About Orelabrutinib
Orelabrutinib is a selective BTK inhibitor for the treatment of cancers and autoimmune diseases, which has been supported by the national special project for the development of major new drugs. Currently, multi-center, multi-indication clinical trials are underway in the US and China with orelabrutinib as monotherapy or in combination therapies. Current clinical data have demonstrated orelabrutinib’s robust efficacy and safety profile. Orelabrutinib’s two indications have been included in priority review by the NMPA.